渤健Biogen (BIIB) 2023年10-K年度报告「NASDAQ」.pdf

《渤健Biogen (BIIB) 2023年10-K年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《渤健Biogen (BIIB) 2023年10-K年度报告「NASDAQ」.pdf（194页珍藏版）》请在三个皮匠报告上搜索。

1、UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549Form 10-KANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2023or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934Commissi

2、on file number:0-19311BIOGEN INC.(Exact name of registrant as specified in its charter)Delaware33-0112644(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)225 Binney Street,Cambridge,MA 02142(617)679-2000(Address,including zip code,and telephone number,

3、including area code,of Registrants principal executive offices)Securities registered pursuant to Section12(b)of the Act:Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which RegisteredCommon Stock,$0.0005 par valueBIIBThe Nasdaq Global Select MarketSecurities registered pursuant to Sect

4、ion12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the SecuritiesAct.Yes x No oIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of theAct.Yes o No xIndicate by check

5、mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was requiredto file such reports),and(2)has been subject to such filing requirements for

6、the past 90 days.Yes x No oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for suchshorter period that the registrant was re